The estimated Net Worth of James Biehl is at least $1.53 Million dollars as of 15 February 2022. Mr. Biehl owns over 20,000 units of Tyme Technologies Inc stock worth over $32,550 and over the last 7 years he sold TYME stock worth over $0. In addition, he makes $1,500,980 as Chief Legal Officer and Corporate Secretary at Tyme Technologies Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Biehl TYME stock SEC Form 4 insiders trading
James has made over 7 trades of the Tyme Technologies Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of TYME stock worth $6,800 on 15 February 2022.
The largest trade he's ever made was buying 20,000 units of Tyme Technologies Inc stock on 15 February 2022 worth over $6,800. On average, James trades about 5,313 units every 61 days since 2017. As of 15 February 2022 he still owns at least 105,000 units of Tyme Technologies Inc stock.
You can see the complete history of Mr. Biehl stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Biehl biography
James Biehl serves as Chief Legal Officer and Corporate Secretary of the Company. He has served as the Chief Legal Officer and Corporate Secretary of Tyme since September 2018. Mr. Biehl served as a member of our Board from March 2017 to September 2018. Prior to joining the Company, Mr. Biehl had been a partner at the law firm of Drinker Biddle & Reath LLP since 1998 in the Corporate and Securities Group. As a corporate lawyer with over 30 years of experience representing public and private companies with structuring, negotiating and managing sophisticated securities and corporate transactional matters, he has extensive experience with federal and state securities laws, public debt and equity financings, mergers and acquisitions, corporate venture transactions, joint ventures and strategic alliances, emerging company formation and management, and corporate governance matters. Mr. Biehl’s industry experience includes representing big pharma, healthcare systems, healthcare consulting firms, consumer products, and medical device companies.
What is the salary of James Biehl?
As the Chief Legal Officer and Corporate Secretary of Tyme Technologies Inc, the total compensation of James Biehl at Tyme Technologies Inc is $1,500,980. There are no executives at Tyme Technologies Inc getting paid more.
How old is James Biehl?
James Biehl is 56, he's been the Chief Legal Officer and Corporate Secretary of Tyme Technologies Inc since 2018. There are 14 older and 4 younger executives at Tyme Technologies Inc. The oldest executive at Tyme Technologies Inc is Gerald Sokol, 77, who is the Independent Director.
What's James Biehl's mailing address?
James's mailing address filed with the SEC is C/O TYME TECHNOLOGIES, INC., 1 PLUCKEMIN WAY - SUITE 103, BEDMINSTER, NJ, 07921.
Insiders trading at Tyme Technologies Inc
Over the last 7 years, insiders at Tyme Technologies Inc have traded over $11,656,990 worth of Tyme Technologies Inc stock and bought 384,831 units worth $412,502 . The most active insiders traders include Steve Hoffman, Michael Demurjian, and Douglas A Michels. On average, Tyme Technologies Inc executives and independent directors trade stock every 8 days with the average trade being worth of $15,104. The most recent stock trade was executed by Michael Demurjian on 6 September 2022, trading 160,000 units of TYME stock currently worth $40,000.
What does Tyme Technologies Inc do?
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system.
With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.
What does Tyme Technologies Inc's logo look like?
Complete history of Mr. Biehl stock trades at Tyme Technologies Inc
Tyme Technologies Inc executives and stock owners
Tyme Technologies Inc executives and other stock owners filed with the SEC include:
-
James Biehl,
Chief Legal Officer and Corporate Secretary -
Michele Korfin,
Chief Operating Officer -
Steve Hoffman,
Chairman of the Board, Chief Executive Officer, Chief Science Officer -
Steven E. Hoffman,
Co-Founder, Chairman & Chief Science Officer -
James Biehl J.D.,
Chief Legal Officer & Sec. -
Dr. Jonathan M. Eckard,
Chief Bus. Officer -
Richard Cunningham,
CEO & Director -
David Carberry,
Independent Director -
Donald Degolyer,
Independent Director -
Gerald Sokol,
Independent Director -
Timothy Tyson,
Independent Director -
Douglas Michels,
Independent Director -
Paul Sturman,
Independent Director -
Jonathan Eckard,
Chief Business Officer -
Giuseppe Del Priore,
Chief Medical Officer -
Barbara Galaini,
Principal Financial Officer, Principal Accounting Officer, Corporate Controller -
Frank L. Porfido,
Chief Financial Officer -
Dr. Jan Marie-Albert Van Tornout M.D., M.Sc.,
Acting Chief Medical Officer -
Dr. John M. Rothman,
Exec. VP of Product Devel. -
John Zucaro P.E.,
Sr. VP of CMC -
Tommy G Thompson,
Director -
Christine D. Baker,
Director -
John M. Rothman,
EVP, Product Development -
Michael Demurjian,
10% owner -
Ben R Taylor,
President, CFO -
Tornout Jan M Van,
Acting Chief Medical Officer -
Christopher F Brown,
10% owner -
Frank L. Porfido,
Chief Financial Officer -
Richard Anthony Cunningham,,
Chief Executive Officer